The FDA has issued a complete response letter for Eli Lilly's Alzheimer's drug donanemab, requesting data from at least 100 patients with 12 months of continued treatment before considering accelerated approval.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.